VANCOUVER, BC / ACCESSWIRE / October 22, 2019 / Canland Health Corp. (the “Company”) today announced that it has closed the previously announced non-brokered private placement (the “Private Placement”) raising gross proceeds of $365,000 from the issuance and sale of 3,650,000 common shares (“Common Shares”) at a price of $0.10 per Common Share. No new insiders were created as a result of this Private Placement.
The Private Placement was previously announced on October 17, 2019.
The Common Shares issued under the Private Placement will be subject to a four month and one day resale restriction. The Company intends to use the net proceeds of the Private Placement for evaluating new opportunities as part of its business model and for working capital purposes.
For further information regarding this news release contact:
C.K. Cheung, CEO
Tel: 416 904 1478
On behalf of the Board of Directors
CANLAND HEALTH CORP.
THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES. THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATED SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.
SOURCE: Canland Health Corp.
View source version on accesswire.com:
https://www.accesswire.com/563796/Canland-Health-Announces-Closing-of-Non-Brokered-Private-Placement
Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…
RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…
CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…